XOMA Royalty (NASDAQ:XOMA) Stock Rating Lowered by Zacks Research

XOMA Royalty (NASDAQ:XOMA) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research firms have also recently weighed in on XOMA. TD Cowen raised XOMA Royalty to a “hold” rating in a report on Friday, February 13th. HC Wainwright decreased their target price on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Benchmark restated a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Finally, Wall Street Zen downgraded shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, XOMA Royalty currently has a consensus rating of “Hold” and an average target price of $61.60.

XOMA Royalty Stock Performance

NASDAQ:XOMA opened at $26.96 on Tuesday. The stock has a market capitalization of $333.76 million, a P/E ratio of 36.43 and a beta of 0.86. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. XOMA Royalty has a 1 year low of $18.35 and a 1 year high of $39.92. The firm has a 50 day moving average of $26.15 and a 200-day moving average of $30.72.

Institutional Investors Weigh In On XOMA Royalty

Several institutional investors have recently modified their holdings of XOMA. Stonepine Capital Management LLC grew its holdings in XOMA Royalty by 17.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after acquiring an additional 22,330 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of XOMA Royalty in the 2nd quarter valued at $370,000. Panagora Asset Management Inc. acquired a new position in shares of XOMA Royalty in the 2nd quarter valued at $463,000. Squarepoint Ops LLC bought a new position in shares of XOMA Royalty in the 4th quarter worth $237,000. Finally, BNP Paribas Financial Markets boosted its position in shares of XOMA Royalty by 266.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,346 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.